Obsessive compulsive disorder (OCD) is characterized by recurrent and intrusive thoughts that are distressing (obsessions) and/or repetitive behaviors or mental acts that the person feels driven to perform (compulsions). OCD has a partly genetic basis. For treatment of OCD, potent serotonin reuptake inhibitor (SRI) drugs (clomipramine (Anafranil), fluvoxamine (Luvox), fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil)), which act on the serotonin transporter protein, are uniquely efficacious. A polymorphism in the promoter region of the gene (SLC6A4) encoding this protein, 1 was recently reported to affect protein expression and to be associated with measures of anxiety and depression 2 and with autism (using a family-controlled transmission disequilibrium test (TDT) design).
2 TDT = 4.83; PϽ0.03). Considering only the 13 SRI drug nonresponders, there were 13 heterozygous parents, of whom 10 transmitted the 'l' allele and three the 's' allele ( 2 TDT = 3.77; PϽ0.052). These data provide preliminary support for association and linkage disequilibrium between the SLC6A4 'l' allele and OCD.
Obsessive-compulsive disorder (OCD) is classified as an anxiety disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). 4 The disorder, which is of unknown etiology, is characterized by recurrent, distressing thoughts that are experienced as intrusive and inappropriate (obsessions) and/or by repetitive behaviors or mental acts that the person feels driven to perform but recognizes as excessive or unreasonable (compulsions). OCD is often chronic and may produce considerable disability. Epidemiological studies suggest it may affect as many as 2-3% of the population at some point during their lifetimes. 5 These rates are more than 20 times higher than previous prevalence estimates and indicate that OCD is more common than schizophrenia and panic disorder.
OCD is familial and heritable. 6 A recent family study demonstrated that the rate of OCD was significantly greater among the first-degree relatives of 100 probands with OCD (10.3%) than among comparison subjects (2%) who were first-degree relatives of 33 psychiatrically unaffected subjects. 7 The rate of chronic tics (Tourette's disorder and chronic multiple tics) was also higher among relatives of probands with OCD (4.6%) than controls (1%). The investigators suggested that some cases of OCD are familial and unrelated to chronic tics, some are familial and related to tic disorders, and in others there appears to be no family history of either OCD or tics.
Although previously viewed as refractory to most therapeutic interventions, significant advances have been made in the pharmacotherapeutics of OCD. 8 In particular, the clear efficacy of potent serotonin reuptake inhibitors (SRIs), including clomipramine, 9 fluvoxamine, 10 fluoxetine, 11 sertraline, 12 and paroxetine, 13 and their greater efficacy when directly compared to drugs that potently inhibit norepinephrine uptake, 14 supports the hypothesized importance of serotonin (5-hydroxytryptamine, 5-HT) in the treatment of OCD. This class of drugs acts on the serotonin transporter protein (5-HTT); the acute blockade of 5-HT uptake into nerve terminals at the 5-HTT by these drugs is likely to be a critical initial event in a series of neurochemical effects that result in improvement of obsessive-compulsive symptoms. The consistent demonstration in OCD of a significant treatment advantage of potent SRIs over other classes of antidepressant and antipanic drugs, drugs with variable effects on acute monoamine reuptake, is without parallel in affective or anxiety disorders research. 14 It was previously postulated that any comprehensive theory about the pathophysiology of OCD must take into consideration this differential treatment response finding. 14 A significant association of depression and anxietyrelated traits with a polymorphism in the human serotonin transporter protein gene (SLC6A4) promoter was recently reported among 505 subjects consisting predominately of European-American male siblings, other family members and volunteers.
2 Subjects with either one or two copies of the 's' (short) allele had higher scores on the NEO personality inventory factor of Neuroticism 15 than did individuals homozygous for the 'l' (long) allele of the SLC6A4 promoter polymorphism. Genotype was also associated with one of five second-order factors, Anxiety, from Cattell's 16PF personality inventory. 16 This polymorphism also has a direct effect on gene regulation.
2
SLC6A4 has extraordinary a priori support as a primary candidate gene influencing risk for OCD: the protein it encodes is a medication target; a polymorphism in the gene affects function; and that polymorphism has been shown to be associated with behavioral phenotypes. We hypothesized that the 's' allele of the SLC6A4 promoter polymorphism would be associated with increased susceptibility to OCD. We have previously reported significant differences in SLC6A4 allele and haplotype frequencies between different populations, 17 demonstrating potential for population stratification for association studies using a case-control design. To control for the effects of population stratification, we used a family-controlled transmission-disequilibrium (TDT) design. 18 The TDT uses family trios composed of affected subjects and their biological parents, and is a test for linkage (or linkage disequilibrium) in the presence of association.
A total of 30 European-American trios, plus four additional complete trios extracted from an 11-member family (see Methods), were included. There was one additional Hispanic trio, not included in most analyses described below, because of the differences in allele frequency by population group seen for this locus. 17 Of the European-American trios, nine had no parents heterozygous at the SLC6A4 promoter polymorphic locus, 14 had one parent heterozygous, and seven had both parents heterozygous. In addition, for the four complete trios drawn from the extended single family, in one case one parent was heterozygous, and in the other three cases both were heterozygous. Thus, there were a total of 35 instances where differing SLC6A4 alleles could be transmitted to affected subjects.
Nine (22.5%) of the 35 patients had a lifetime history of Tourette's disorder or chronic multiple tics (motor or vocal) or a first-degree relative with Tourette's disorder; based upon this comorbidity, these patients were classified as having 'tic-related' OCD. 19 Twentytwo of the patients were classified as responders to SRI treatment and 13 were considered nonresponders. Of the 35 heterozygous parents, 24 transmitted the 'l' SLC6A4 promoter allele, and 11 transmitted the 's' allele ( The results of this study provide preliminary evidence for linkage disequilibrium between OCD and the serotonin transporter protein gene (SLC6A4) 'l' allele. This finding lends support to a model of disease which links a variation in a gene, SLC6A4, which encodes a medication target, the serotonin transporter protein, with a disorder, OCD, in which drugs that act at the serotonin transporter protein (the potent SRIs), are the preferred therapeutic agents.
Previous studies have also used molecular biological techniques to determine the genetic contributions to OCD. In a recent study, no variation in amino acid sequence in the primary structure of the 5-HTT coding region were identified among OCD patients or healthy controls. 20 However, the SLC6A4 promoter region was not examined in that study. In a case-control study, Karayiorgou et al 21 found in a sample of 73 OCD patients (18 with comorbid tics) and 148 matched controls, that a common functional allele of the gene for catechol-O-methyltransferase (COMT), which results in a 3-to 4-fold reduction in enzyme activity, is significantly associated in a recessive manner with susceptibility to OCD, particularly in males.
As in OCD, stereotyped, ritualistic behavior is a common feature of autistic disorder. 22 Potent SRIs have recently been shown to be effective for reducing the interfering repetitive thoughts and behavior of adults with autistic disorder. 23 Importantly, Cook et al 3 recently reported the preferential transmission of the 's' variant of the SLC6A4 promoter polymorphism in 86 trios consisting of probands with autistic disorder and both parents; this finding provided preliminary evidence of linkage and association between SLC6A4 and autistic disorder. Contrary to our initial hypothesis, the long 'l' allele rather than the short 's' allele was found to be preferentially transmitted from parents to probands with OCD in this study. This hypothesis was, however, based on the report of an association between the 's' allele and neuroticism; results inconsistent with such a relationship have been reported more recently. 24 There are other reports consistent with effects of this polymorphism on phenotype, such as the report by Collier et al showing an association of the 's' allele with affective disorders in a large sample 25 and the study by Cook et al 3 discussed above. In retrospect, since the finding of an association with anxiety-related phenotypes has not yet been confirmed, while other behavioral effects for this polymorphism have been observed, it is clear that a hypothesis relating to direction of effect for OCD was premature. Some possible explanations include: (a) direct functional effects of this polymorphism, but primarily for phenotypes other than normal-range anxiety; (b) direct functional effects of this polymorphism on anxiety but in different directions in the normal range 2 and in the context of OCD; and (c) an effect through some other polymorphism in linkage disequilibrium with this SLC6A4 promoter polymorphism. (This hypothesized polymorphism is unlikely to be the SLC6A4 intron 2 VNTR, 26 as one study has reported that there was no linkage disequilibrium between the promoter polymorphism and the intron 2 polymorphism in an EA control population.)
We conclude that these data support association and linkage disequilibrium between the 'l' allele of the SLC6A4 promoter polymorphism and OCD. This constitutes preliminary evidence for either a direct effect of this polymorphism as a risk factor for OCD, or the existence of another polymorphism influencing risk close enough to this polymorphic site to be in linkage disequilibrium with it. It is important now to extend these results in larger samples (using the TDT or other linkage methods given the demonstrated population variation in allele frequencies at this locus) to determine if the finding can be replicated.
Methods

Subjects
Subjects included consecutive patients evaluated and treated at the Yale Adult OCD Clinic of the Clinical Neuroscience Research Unit at the Connecticut Mental Health Center, New Haven, CT. All subjects met DSM-IV criteria for OCD and had biological parents willing to participate and give blood samples for genotyping. Only subjects with obsessive-compulsive symptoms of at least one year in duration and of at least moderate severity as defined by a rating of 'moderate' or greater on the global severity item of the Clinical Global Impression (CGI) scale 27 were included in the study. Compared to many clinical samples, the present one tended to show severe symptoms as the clinic is a tertiary referral source. Subjects with major depression were included in the study only if the obsessive-compulsive symptoms were most prominent and only if the onset of OCD antedated the onset of depression.
Subjects were excluded if they presented with a movement disorder other than chronic tics, such as tardive dyskinesia or chorea; schizophrenia or other psychotic symptoms; primary body dysmorphic disorder; a documented history of Sydenham's chorea; alcohol or other substance abuse within the last 6 months; or a history of psychosurgery, encephalitis, or significant head trauma.
Thirty-two families participated in the study, including 31 family trios and a small family from which eleven individuals were genotyped and of whom six were affected (four complete trios resulted from this family). The probands included 17 women and 18 men of whom 34 were European-American and one was Hispanic. They ranged in age from 18-51 years (mean ± SD, 33.0 ± 8.5 years). The age of onset of OCD for the probands ranged from 7-36 years (mean 18.4 ± 7.0 years) and the duration of illness ranged from 3-36 years (mean 14.3 ± 9.6 years).
Clinical assessment procedures
Each subject was interviewed using relevant portions of the Schedule for Tourette's Syndrome and Other Behavioral Syndromes (STOBS) modified for DSM-IV. 28 This structured interview is based largely on the Diagnostic Interview Schedule, 29 but the assessment of OCD and tics has been extensively modified and expanded. The STOBS also provides coverage for all major psychiatric disorders and documents the natural history of obsessive-compulsive symptoms and tic behaviors. Each subject and each subject's available first-degree relatives were also asked to report on each of their first-degree relatives' psychiatric symptoms using a semi-structured format. Final diagnoses for probands were made independently following the best estimate diagnostic procedures developed by Leckman et al. 30 At the time of admission to the OCD clinic each patient was administered the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) 31, 32 which determines the severity of obsessive-compulsive symptoms (range 0-40). Baseline Y-BOCS scores ranged from 19-39 (mean 29.5 ± 4.9); this corresponds to moderate-to-severe symptomatology.
Drug treatment
All of the subjects received at least one adequate treatment trial with a potent SRI (ie, at least 12 weeks of clomipramine 150-250 mg day −1 ; fluvoxamine 150-300 mg day −1 ; fluoxetine 40-80 mg day
; sertraline 100-200 mg day ). To be considered an SRI treatment responder, patients had to meet the following criteria: (1) 35% or greater improvement on the Y-BOCS and a final Y-BOCS score of Ͻ16; (2) a final CGI score of 'much improved' or 'very much improved'; and (3) consensus of the treating clinician and two of the primary investigators that the patient's condition was improved.
Twenty milliliters of blood were drawn from each proband and parent for DNA extraction. Informed consent was obtained from all subjects.
Genotyping
This polymorphism was described by Heils et al, 1 but we used different PCR primers based on reported sequence, 1 JP (5Ј-ATG CCA GCA CCT AAC CCC TAA TGT-3Ј) and GR (5Ј-GG ACC GCA AGG TGG GCG GGA-3Ј). PCR conditions were reported previously. 17 
Statistical methods
The TDT employs family trios composed of affected probands and their two biological parents. 18 For parents heterozygous for an allele of interest, instances of transmission of that allele are counted and compared with a chance distribution (ie, 50%). Significant deviation from this chance distribution, tested by the 2 TDT , is evidence for linkage disequilibrium between the phenotype and the allele of interest. 
